Soluble B-cell activation marker of sCD27 and sCD30 and future risk of B-cell lymphomas: A nested case-control study and meta-analyses
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Soluble B-cell activation marker of sCD27 and sCD30 and future risk of B-cell lymphomas: A nested case-control study and meta-analyses
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 138, Issue 10, Pages 2357-2367
Publisher
Wiley
Online
2015-12-19
DOI
10.1002/ijc.29969
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Soluble levels of CD27 and CD30 are associated with risk of non-Hodgkin lymphoma in three Chinese prospective cohorts
- (2015) Bryan A. Bassig et al. INTERNATIONAL JOURNAL OF CANCER
- Elevated serum sCD23 and sCD30 up to two decades prior to diagnosis associated with increased risk of non-Hodgkin lymphoma
- (2015) M P Purdue et al. LEUKEMIA
- Soluble CD30: A Possible Serum Tumor Marker for Primary Effusion Lymphoma
- (2013) Manthana Michai et al. Asian Pacific Journal of Cancer Prevention
- Circulating Soluble CD27 and CD30 in Workers Exposed to 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)
- (2013) F. Saberi Hosnijeh et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Serum Biomarkers of Immune Activation and Subsequent Risk of Non-Hodgkin B-Cell Lymphoma among HIV-Infected Women
- (2013) S. K. Hussain et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Reliability of Serum Biomarkers of Inflammation from Repeated Measures in Healthy Individuals
- (2012) S. L. Navarro et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Markers of B-Cell Activation in Relation to Risk of Non-Hodgkin Lymphoma
- (2012) A. J. De Roos et al. CANCER RESEARCH
- Serum soluble CD27 level is associated with outcome in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone
- (2012) Naoe Goto et al. LEUKEMIA & LYMPHOMA
- Circulating Soluble CD30 and Future Risk of Lymphoma; Evidence from Two Prospective Studies in the General Population
- (2011) R. Vermeulen et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Prediagnostic Serum Levels of Cytokines and Other Immune Markers and Risk of Non-Hodgkin Lymphoma
- (2011) M. P. Purdue et al. CANCER RESEARCH
- Intra-individual variability over time in serum cytokine levels among participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
- (2011) Jonathan N. Hofmann et al. CYTOKINE
- Occupational exposure to trichloroethylene is associated with a decline in lymphocyte subsets and soluble CD27 and CD30 markers
- (2010) Qing Lan et al. CARCINOGENESIS
- CD30+ lymphoproliferative disorders
- (2010) L. de Leval et al. HAEMATOLOGICA
- Cancer biomarkers in HIV patients
- (2010) Richard F Ambinder et al. Current Opinion in HIV and AIDS
- A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma
- (2009) M. P. Purdue et al. BLOOD
- Atopic Disease and Risk of Non-Hodgkin Lymphoma: An InterLymph Pooled Analysis
- (2009) C. M. Vajdic et al. CANCER RESEARCH
- Reproducibility and Correlations of Multiplex Cytokine Levels in Asymptomatic Persons
- (2008) H.-L. Wong et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Reproducibility of serum cytokines and growth factors
- (2008) Yian Gu et al. CYTOKINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started